Protocol Ledger

NCT05571059 · Phase II · RECRUITING

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Interventional Phase II clinical trial protocol NCT05571059 sponsored by Cumberland Pharmaceuticals in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-01-31 Enrollment: 128 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05571059
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)128 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05571059
Protocol FieldVerified Registry Value
NCT IdentifierNCT05571059
Consolidated Lead SponsorCumberland Pharmaceuticals
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment128 participants (ESTIMATED)
Registered Start Date2024-01-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI